An experimental Alzheimer’s drug outperforms one just approved by the FDA

Patients in the early stages of Alzheimer’s may soon have a new option to stave off the loss of memory and thinking. In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer’s by about 35%, scientists reported at the Alzheimer’s Association International Conference in Amsterdam. The result, published simultaneously in the journal JAMA, suggests…

Read more